https://www.selleckchem.com/pr....oducts/NVP-ADW742.ht
mortality within 14 days. Ceftazidime/avibactam is a potentially useful therapeutic choice for cases caused by invitro susceptible CRKP strains. Prior exposure to carbapenems, longer hospital stay, and the presence of liver cirrhosis predicted CRKP instead of CSKP mBSI. Even with colistin therapy, CRKP mBSIs was still associated with a very high risk of mortality within 14 days. Ceftazidime/avibactam is a potentially useful therapeutic choice for cases caused by in vitro susceptible CRKP strains. To analyze the amount of variation in
Curtir
Comentario
Compartilhar
